Tanaka Y - Search Results

1

Baricitinib for systemic lupus erythematosus - Authors' reply.

Wallace DJ, Furie RA, Tanaka Y, de Bono S, Hoffman RW. Wallace DJ, et al. Among authors: tanaka y. Lancet. 2019 Feb 2;393(10170):402-403. doi: 10.1016/S0140-6736(18)32749-1. Lancet. 2019. PMID: 30712893 No abstract available.

2

[Successful treatment of intravenous cyclophosphamide pulse therapy for systemic lupus erythematosus complicated with steroid-resistant hemolytic anemia].

Tokunaga M, Saito K, Nakatsuka K, Nakayamada S, Nakano K, Tsujimura S, Ota T, Tanaka Y. Tokunaga M, et al. Among authors: tanaka y. Nihon Rinsho Meneki Gakkai Kaishi. 2003 Oct;26(5):304-9. doi: 10.2177/jsci.26.304. Nihon Rinsho Meneki Gakkai Kaishi. 2003. PMID: 14635405 Japanese.

3

Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus.

Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y. Tsujimura S, et al. Among authors: tanaka y. Arthritis Rheum. 2005 Jun;52(6):1676-83. doi: 10.1002/art.21032. Arthritis Rheum. 2005. PMID: 15934077 Free article.

4

Attempt to correct abnormal signal transduction in T lymphocytes from systemic lupus erythematosus patients.

Fujii Y, Fujii K, Tanaka Y. Fujii Y, et al. Among authors: tanaka y. Autoimmun Rev. 2006 Feb;5(2):143-4. doi: 10.1016/j.autrev.2005.09.004. Epub 2005 Sep 19. Autoimmun Rev. 2006. PMID: 16431347 Review.

5

Activation signal transduction by beta1 integrin in T cells from patients with systemic lupus erythematosus.

Nakayamada S, Saito K, Nakano K, Tanaka Y. Nakayamada S, et al. Among authors: tanaka y. Arthritis Rheum. 2007 May;56(5):1559-68. doi: 10.1002/art.22581. Arthritis Rheum. 2007. PMID: 17469136 Free article. Clinical Trial.

6

A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus.

Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, Shima Y, Takada K, Matsumoto I, Saito K, Koike T. Tanaka Y, et al. Mod Rheumatol. 2007;17(3):191-7. doi: 10.1007/s10165-007-0565-z. Epub 2007 Jun 20. Mod Rheumatol. 2007. PMID: 17564773 Clinical Trial.

7

Serum brain-derived neurotrophic factor levels as a novel biological marker for the activities of psychiatric symptoms in systemic lupus erythematosus.

Ikenouchi-Sugita A, Yoshimura R, Okamoto T, Umene-Nakano W, Ueda N, Hori H, Katsuki A, Saito K, Tanaka Y, Nakamura J. Ikenouchi-Sugita A, et al. Among authors: tanaka y. World J Biol Psychiatry. 2010 Mar;11(2):121-8. doi: 10.3109/15622970903521131. World J Biol Psychiatry. 2010. PMID: 20109107

8

Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.

Iwata S, Saito K, Tokunaga M, Yamaoka K, Nawata M, Yukawa S, Hanami K, Fukuyo S, Miyagawa I, Kubo S, Tanaka Y. Iwata S, et al. Among authors: tanaka y. J Rheumatol. 2011 Apr;38(4):633-41. doi: 10.3899/jrheum.100729. Epub 2010 Dec 15. J Rheumatol. 2011. PMID: 21159836

9

[Progress in B-cell targeting therapy for the treatment of systemic lupus erythematosus].

Tanaka Y. Tanaka Y. J UOEH. 2011 Jun 1;33(2):173-81. doi: 10.7888/juoeh.33.173. J UOEH. 2011. PMID: 21702122 Review. Japanese.

10

A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/β₂ glycoprotein I and anti-phosphatidylserine/prothrombin autoantibodies.

Hirakawa E, Saito K, Hirata S, Atsumi T, Koike T, Tanaka Y. Hirakawa E, et al. Among authors: tanaka y. Mod Rheumatol. 2012 Sep;22(5):769-73. doi: 10.1007/s10165-011-0563-z. Epub 2011 Nov 29. Mod Rheumatol. 2012. PMID: 22124547

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15,350 results

Search Page

Filters